GRAL — GRAIL, Inc.

GRAIL Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $40.8 million, up 28% year-over-year, driven primarily by screening revenue of $39.8 million (up 37%).
• Test Volume: Over 56,000 Galleri tests sold, representing a 50% increase from Q1 2025.
• Net Loss: $93.2 million, an improvement of 12% compared to the previous year.
• Adjusted Gross Profit: $19.7 million, up 38% year-over-year.
• Adjusted EBITDA: Negative $79.9 million, but improved by 19% compared to Q1 2025.
• Cash Position: $823.1 million, providing financial flexibility for growth.

2. Strategic Updates and Business Highlights:

• Continued strong commercial momentum with expanding physician adoption and health system engagement.
• Significant partnerships established with health systems like Dana-Farber, Rush, OHSU, and Cleveland Clinic.
• Integration with Quest and Epic EHR platforms to streamline ordering and result management.
• FDA PMA submission for Galleri accepted for review, focusing on test performance and safety.
• Upcoming data presentations at the 2026 ASCO Annual Meeting, showcasing findings from the NHS-Galleri trial and PATHFINDER 2 study.

3. Forward Guidance and Outlook:

• Reiterated revenue growth guidance for 2026 of 22% to 32%.
• Anticipated sales force expansion to be completed by mid-year, expected to drive further commercial momentum.
• Integration with Epic expected to enhance health system adoption in the second half of the year.

4. Bad News, Challenges, or Points of Concern:

• ASP (Average Selling Price) has declined, attributed to pricing strategies aimed at population scale and increased discounting programs.
• Competitive pressures are rising, with other companies ramping up direct-to-consumer advertising, which could impact market dynamics.
• Concerns regarding the uptake of new partnerships and digital health initiatives, as the company is still assessing their impact on revenue growth.
• The NHS-Galleri trial data received mixed feedback, leading to questions from stakeholders that need addressing post-ASCO.

5. Notable Q&A Insights:

• The potential for Galleri to be eligible for the FDA and CMS rapid pathway was discussed, with optimism about its breakthrough device status.
• Stakeholder feedback on NHS-Galleri data has been mixed, with oncologists showing increased interest in the reduction of Stage IV cancer diagnoses.
• The sales force expansion is aimed at enhancing provider engagement, with training planned post-ASCO to address questions raised by the NHS-Galleri data.
• The company is cautious about guidance, citing uncertainties in digital health partner uptake and competitive pressures as factors influencing their outlook.

Overall, GRAIL reported strong growth in revenue and test volumes while navigating challenges related to pricing, competition, and stakeholder perceptions of clinical data. The company is positioned for continued growth with strategic partnerships and upcoming data presentations.